Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)

SHE:300683 Revenue

Wuhan Hiteck Biological Pharma Co.,Ltd had revenue of 88.24M CNY in the quarter ending September 30, 2026, a decrease of -39.90%. This brings the company's total for the last twelve months to 433.31M, down -30.10% year-over-year. In the year 2025, Wuhan Hiteck Biological Pharma Co.,Ltd had annual revenue of 541.45M, down -16.57%. That makes Wuhan Hiteck Biological Pharma Co.,Ltd the 25,972nd largest company in the world by revenue and 4,593rd in China.

• Revenue (ttm): 433.31M
• Revenue Growth: -30.10%
• P/S Ratio: 7.14
• Revenue / Employee: n/a
• Employees: 958
• Market Cap: 3.09B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Medical Technical Services Reporting Segment 257.25M 45.4%
• Biopharma 231.95M 40.9%
• Production and Sales of Raw Materials and Pharmaceutical Intermediates 64.72M 11.4%
• Other 9.07M 1.6%
• in Vitro Diagnostic Reagents 4.17M 0.7%

By Geography

Chart

• China 540.51M 99.8%
• Overseas 937.79K 0.2%

Fiscal year ended Dec 31, 2025 See the full SHE:300683 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	541.45M	-107.52M	-16.57%
Dec 31, 2024	648.97M	46.69M	7.75%
Dec 31, 2023	602.28M	-86.34M	-12.54%
Jan 1, 2023	688.63M	73.94M	12.03%
Jan 1, 2022	614.68M	90.56M	17.28%

Data Source: S&P Global Market Intelligence Last updated: Oct 22, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 24, 2026

Data Sources Report a data error